VCYT logo

VCYT
Veracyte Inc

1,265
Mkt Cap
$3.61B
Volume
1.4M
52W High
$50.71
52W Low
$22.61
PE Ratio
41.45
VCYT Fundamentals
Price
$45.03
Prev Close
$45.19
Open
$45.46
50D MA
$34.97
Beta
1.52
Avg. Volume
697,102.77
EPS (Annual)
$0.8235
P/B
2.67
Rev/Employee
$684,960.27
$3,018.89
Loading...
Loading...
News
all
press releases
Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that it will host a conference call and webcast on Monday, June 1, 2026 at 8:30 a.m. ET to discuss data from two significant phase III clinical trials using its Prosigna Breast and Decipher Prostate tests that will...
News Placeholder
More News
News Placeholder
OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer
Veracyte, Inc. (NASDAQ: VCYT), a leading cancer diagnostics company, announced today that data from two significant phase III clinical trials using its Prosigna Breast and Decipher Prostate tests will be presented at the 2026 ASCO Annual Meeting in Chicago, taking place May 29 June 2. The OPTIMA...
News Placeholder
Veracyte to Participate in Upcoming Investor Conferences
Veracyte, Inc. (Nasdaq: VCYT) announced today that the company will be participating in the following investor conferences. William Blair 46th Annual Growth Stock Conference Chicago, IL Presentation...
News Placeholder
Why Veracyte (VCYT) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
News Placeholder
Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its TrueMRD Monitoring Test has received coverage from the Centers for Medicare & Medicaid Services (CMS...
News Placeholder
Why Veracyte Stock Is Skyrocketing Higher This Week
Key PointsVeracyte grew revenue by 21% in Q1 and saw earnings per share quadruple from last year, as margins ballooned...
News Placeholder
Veracyte (VCYT) Crossed Above the 200-Day Moving Average: What That Means for Investors
Good things could be on the horizon when a stock surpasses the 200-day simple moving average. How should investors react?
News Placeholder
Veracyte (NASDAQ:VCYT) Shares Gap Up Following Strong Earnings
Veracyte (NASDAQ:VCYT) Shares Gap Up After Strong Earnings...
News Placeholder
Deja Vu All Over Again: Futures Surge, Oil Tumbles On Iran Deal Optimism, Tech Rally
Deja Vu All Over Again: Futures Surge, Oil Tumbles On Iran Deal Optimism, Tech Rally US equity futures are up big this morning and making fresh all time highs, led by tech companies, while oil prices...
News Placeholder
Veracyte Q1 Earnings Call Highlights
Veracyte (NASDAQ:VCYT) reported first-quarter 2026 results that management said marked an "excellent start" to the year, driven by double-digit growth in both revenue and test volume, improved profitability and progress toward two major product launches planned for later in 2026. Marc Stapley, Vera...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available